CD8A and cancer: There was increasing evidence that combined treatment with immunomodulatory doses of EGCG could enhance the immune response of specific CD8+ T lymphocytes and CD4+ Th1 lymphocytes induced by DNA vaccine, and provide long-term anti-cancer protection for treated mice, causing a more excellent cure rate compared to monotherapy (30, 262).